GlassScriptPhysician profile
James H Boyd
NPI 1215928114
$1,971.71
in general payments reported to CMS, 2019-2025
29 companies · $537 in 2025
The $537 reported for 2025 was more than what 77% of Plastic Surgery Within The Head & Neck providers received nationally (typical 2025 total: $238).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $34.66 · 2022: $434 · 2023: $285 · 2024: $256 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $273.56 | 2019-2025 | Audion Et Dilation System |
| Regeneron Healthcare Solutions, INC. | $224.05 | 2022-2025 | Libtayo, Dupixent |
| Merck Sharp & Dohme LLC | $174.31 | 2019-2025 | Keytruda |
| Depuy Synthes Sales INC. | $149.76 | 2023-2025 | Matrixmandible |
| Tactile Systems Technology INC | $148.63 | 2025 | Nimbl, Flexitouch Plus |
| Hologic Sales and Service, LLC | $91.54 | 2023-2025 | Coolseal Generator |
| Eisai INC. | $86.94 | 2023-2025 | |
| Emd Serono, INC. | $86.34 | 2019-2024 | Bavencio |
| Genzyme Corporation | $84.21 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $83.41 | 2022-2023 | Tagrisso, Calquence |
| Glaxosmithkline, LLC. | $73.85 | 2022-2025 | Nucala |
| Amgen INC. | $72.09 | 2019-2023 | Lumakras |
| Aerin Medical INC. | $66.99 | 2019-2023 | |
| Abbvie INC. | $51.57 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.23 | 2024 | Iclusig |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $38.72 | 2024-2025 | Pemazyre, Monjuvi |
| Janssen Biotech, INC. | $29.76 | 2024 | Talvey, Darzalex, Tecvayli |
| Karl Storz Endoscopy-America | $25.46 | 2019 | |
| Beigene USA, INC. | $24.64 | 2025 | Brukinsa |
| Osiris Therapeutics INC. | $18.14 | 2019 | |
| Kyowa Kirin, INC. | $17.37 | 2023 | Poteligeo |
| Smith+Nephew, INC. | $16.38 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.03 | 2019 | |
| Pfizer INC. | $13.79 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.14 | 2024 | Voquezna |
| Lilly USA, LLC | $12.84 | 2022 | |
| Optinose US, INC. | $11.71 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.28 | 2019 | |
| Olympus America INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.